Monitoring DNA markers in blood to predict colorectal cancer return after surgery
Part of Cancer, Digestive system clinical trials.
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have colorectal cancer that has spread to the lining of the abdomen (peritoneal metastases)
- You have had surgery to remove all visible cancer in the abdomen and the original tumor in the colon or rectum
- You are in good enough health to have surgery, with no severe heart or lung problems
- You have no other active cancer (except treated skin or cervical cancer)
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at metabolic biomarkers in blood and tumor tissue to help detect colorectal cancer earlier, predict outcomes, and monitor for recurrence. It includes both people newly diagnosed with colorectal cancer and healthy volunteers for comparison.
This study looks at a blood “DNA” test to see if it can help monitor colorectal cancer after surgery. It may benefit you by improving how doctors track cancer during routine follow-up visits.
This trial uses a blood test (liquid biopsy) to look for tiny bits of cancer DNA remaining after surgery. It aims to see if this test can help guide follow-up and treatment decisions for people with colorectal cancer.
This study looks at colorectal cancer patients who are planning curative surgery and collects related outcomes and lab “biomarker” information to better understand the disease. Your participation may help researchers connect test results to treatment results over time.
This study checks a “cell-free tumor DNA” blood test to see if cancer mutations can predict relapse after surgery for early colorectal cancer. If results look risky, they may help guide closer follow-up and future treatment decisions.
This study looks at special tiny cell-signal particles (called exosomes) and related pathways to understand colorectal cancer. Your results from samples may help researchers learn how these signals relate to the disease after surgery.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.